GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
August 2021
in “
Frontiers in Endocrinology
”
GLP-1 receptor agonists Dulaglutide Liraglutide Semaglutide Polycystic Ovary Syndrome PCOS insulin resistance obesity gut hormones regional body fat stores nonalcoholic fatty liver disease NAFLD hepatic lipotoxicity inflammatory response acute pancreatitis pancreatic cancer Trulicity Victoza Ozempic
Studysummary This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on frontiersin.org →